Prevention in action:five priorities for integrating pharmacogenomics into clinical practice

Abstract Pharmacogenomics holds promise for enhancing drug safety and efficacy, paving the way for more precise, patient-centred therapeutic approaches supporting prevention in public health. However, its integration into routine healthcare remains limited across Europe. A European multidisciplinary expert workshop was held in Amsterdam in January 2025, to share experiences and define priorities in the face of challenges for the integration of pharmacogenomics testing. Based on the workshop findings, this paper explores what stakeholders need to further implement pharmacogenomic testing across healthcare systems in the coming decade. A European expert workshop brought together 55 participants from 10 countries, including 14 speakers representing policy, healthcare, academia, patient representation and industry. The paper focuses on 3 themes to implement pharmacogenomic testing: (1) evidence for testing, (2) acceptability and awareness, and (3) integration into healthcare systems. Based on expert discussions five key challenges and priorities were identified for advancing pharmacogenomics: 1) robust health economic evaluations to support funding decisions, 2) targeted education and training for healthcare professionals, and raising public and healthcare professional awareness of pharmacogenomics testing, 3) investment in ICT and data infrastructure to support data sharing, 4) development of clear policies, and stronger cross-border collaboration and 5) equitable access and scalable integration of testing. Overcoming barriers such as reimbursement issues, policy misalignment, and regional differences will require coordinated, multi-stakeholder efforts guided by informative key indicators. Moving forward, collaboration throughout the implementation pathway will be crucial to advance pharmacogenomic testing as key part of personalised prevention in public health enhancing treatment efficacy and preventing medication-related harm. Key messages • A European workshop identified 5 priorities for implementing pharmacogenomic testing. • Advancing pharmacogenomic testing requires health economic evaluations, education, investment in ICT and policies.